Ekaterina Safroneeva1, Lukas Balsiger2, David Hafner1, Claudia E Kuehni1, Marcel Zwahlen1, Sven Trelle3, Sébastien Godat4, Luc Biedermann5, Thomas Greuter5,6, Stephan Vavricka5, Alex Straumann5, Alain M Schoepfer4. 1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 2. Division of Internal Medicine, Kantonsspital Langenthal, Solothurn, Switzerland. 3. Institute of Social and Preventive Medicine, Clinical Trials Unit Bern, University of Bern, Bern, Switzerland. 4. Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. 5. Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. 6. Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Well informed patients who are in cohesive partnership with physicians and who have realistic expectations towards therapy are more likely to be adherent, which results in better disease control. AIM: To assess which therapy goals adults with eosinophilic oesophagitis consider relevant. METHODS: Following refinement during three focus groups, a study brochure and questionnaire were sent to 148 patients. Patients ranked the importance (five levels) of short-term (in the next 3 months) and long-term (≥1 year) treatment effect on symptoms, quality of life (QoL), histologically-detected inflammation and fibrosis, endoscopically-detected inflammation, and stricture formation as well as achieving histological remission while asymptomatic. Patients' characteristics associated with treatment goals were identified using logistic regression. RESULTS: Of 109 respondents (mean age 43 years), 85 were men. Over 90% chose symptoms and QoL improvement as important short- and long-term therapy goals. A greater proportion attributed more importance to long-term reduction in endoscopic (90% vs 73%, P < 0.001) and histological (81% vs 62%, P = 0.002) inflammation, and histologically-detected fibrosis (79% vs 64%, P = 0.018) when compared to short-term reduction in these features. Patients (88%) ranked achieving histological remission while being asymptomatic as important. Gender, therapy use, education level, QoL, symptom severity, and history of dilation were associated with patients' choice of treatment goals. CONCLUSIONS: Patients attributed most importance to improvement in symptoms and QoL. Reduction in biological activity was judged less important, but more relevant in the long- compared to the short-term.
BACKGROUND: Well informed patients who are in cohesive partnership with physicians and who have realistic expectations towards therapy are more likely to be adherent, which results in better disease control. AIM: To assess which therapy goals adults with eosinophilic oesophagitis consider relevant. METHODS: Following refinement during three focus groups, a study brochure and questionnaire were sent to 148 patients. Patients ranked the importance (five levels) of short-term (in the next 3 months) and long-term (≥1 year) treatment effect on symptoms, quality of life (QoL), histologically-detected inflammation and fibrosis, endoscopically-detected inflammation, and stricture formation as well as achieving histological remission while asymptomatic. Patients' characteristics associated with treatment goals were identified using logistic regression. RESULTS: Of 109 respondents (mean age 43 years), 85 were men. Over 90% chose symptoms and QoL improvement as important short- and long-term therapy goals. A greater proportion attributed more importance to long-term reduction in endoscopic (90% vs 73%, P < 0.001) and histological (81% vs 62%, P = 0.002) inflammation, and histologically-detected fibrosis (79% vs 64%, P = 0.018) when compared to short-term reduction in these features. Patients (88%) ranked achieving histological remission while being asymptomatic as important. Gender, therapy use, education level, QoL, symptom severity, and history of dilation were associated with patients' choice of treatment goals. CONCLUSIONS:Patients attributed most importance to improvement in symptoms and QoL. Reduction in biological activity was judged less important, but more relevant in the long- compared to the short-term.
Authors: Joy W Chang; Vincent L Chen; Joel H Rubenstein; Evan S Dellon; Lauren P Wallner; Raymond De Vries Journal: Dis Esophagus Date: 2022-06-15 Impact factor: 2.822
Authors: Philipp Schreiner; Luc Biedermann; Thomas Greuter; Benjamin L Wright; Alex Straumann Journal: Dis Esophagus Date: 2021-01-11 Impact factor: 3.429
Authors: Nicole Chang; Soha Raja; Renee Betancourt; Cara Randall; Staci Keene; Amy Lilly; Mark Fowler; John T Woosley; Nicholas J Shaheen; Evan S Dellon Journal: Dig Dis Sci Date: 2021-01-25 Impact factor: 3.487
Authors: Christopher Ma; Alain M Schoepfer; Evan S Dellon; Albert J Bredenoord; Mirna Chehade; Margaret H Collins; Brian G Feagan; Glenn T Furuta; Sandeep K Gupta; Ikuo Hirano; Vipul Jairath; David A Katzka; Rish K Pai; Marc E Rothenberg; Alex Straumann; Seema S Aceves; Jeffrey A Alexander; Nicoleta C Arva; Dan Atkins; Luc Biedermann; Carine Blanchard; Antonella Cianferoni; Constanza Ciriza de Los Rios; Frederic Clayton; Carla M Davis; Nicola de Bortoli; Jorge A Dias; Gary W Falk; Robert M Genta; Gisoo Ghaffari; Nirmala Gonsalves; Thomas Greuter; Russell Hopp; Karen S Hsu Blatman; Elizabeth T Jensen; Doug Johnston; Amir F Kagalwalla; Helen M Larsson; John Leung; Hubert Louis; Joanne C Masterson; Calies Menard-Katcher; Paul A Menard-Katcher; Fouad J Moawad; Amanda B Muir; Vincent A Mukkada; Roberto Penagini; Robert D Pesek; Kathryn Peterson; Philip E Putnam; Alberto Ravelli; Edoardo V Savarino; Christoph Schlag; Philipp Schreiner; Dagmar Simon; Thomas C Smyrk; Jonathan M Spergel; Tiffany H Taft; Ingrid Terreehorst; Tim Vanuytsel; Carina Venter; Mario C Vieira; Michael Vieth; Berber Vlieg-Boerstra; Ulrike von Arnim; Marjorie M Walker; Joshua B Wechsler; Philip Woodland; John T Woosley; Guang-Yu Yang; Noam Zevit; Ekaterina Safroneeva Journal: J Allergy Clin Immunol Date: 2021-07-06 Impact factor: 10.793